Search results
Results From The WOW.Com Content Network
In 2000, Alembic received ISO 14000 certification for its Vadodara facility. [2] In 2010, Alembic Pharmaceutical Ltd. demerged from Alembic Ltd. subsequent to the allotment of 133,515,914 equity shares of ₹2 each to the shareholders of Alembic Ltd. This made the shareholding of Alembic Ltd. in Alembic Pharmaceutical reduce from 100% to 29.18% ...
A drug recall removes a prescription or over-the-counter drug from the market. Drug recalls in the United States are made by the FDA or the creators of the drug when certain criteria are met. When a drug recall is made, the drug is removed from the market and potential legal action can be taken depending on the severity of the drug recall.
Alembic Group is an Indian conglomerate headquartered in Vadodara.It was founded in 1907 [5] and was initially known as Alembic Chemical Works Company Ltd. The company was founded by T. K. Gajjar, A. S. Kotibhaskar and B. D. Amin. [6] It is one of the oldest industrial houses in India and has a diversified portfolio of business. [2]
Pharmaceutical recalls skyrocketed to 517 events in 2023 compared to 363 the year before, a 42.4% increase, according to Sedgwick’s State of the Nation 2024 Product Safety and Recall report ...
This contamination was not detected until 2018. The incident, according to medicinal chemist and pharmaceutical industry blogger Dr. Derek Lowe, points to a greater problem. Generic drug manufacturers often change the way in which prescription drug ingredients are made in order to lower costs of making them, so this kind of contamination may be ...
India's Alembic Pharmaceuticals on Tuesday reported second-quarter profit roughly in line with estimates, as higher sales in its domestic and overseas markets offset a jump in expenses. The ...
Japanese authorities on Wednesday ordered drugmaker Kobayashi Pharmaceutical to recall three dietary supplement products containing red yeast rice, or beni koji, after they were linked to two deaths.
Drugs or medicines may be withdrawn from commercial markets because of risks to patients, but also because of commercial reasons (e.g. lack of demand and relatively high production costs).